96 related articles for article (PubMed ID: 16575466)
1. A disconnect between antitumor and antiangiogenic effects of fluvastatin in vitro and in vivo.
Klement H; Rak J
Neoplasma; 2006; 53(2):111-8. PubMed ID: 16575466
[TBL] [Abstract][Full Text] [Related]
2. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis.
Horiguchi A; Sumitomo M; Asakuma J; Asano T; Asano T; Hayakawa M
Clin Cancer Res; 2004 Dec; 10(24):8648-55. PubMed ID: 15623649
[TBL] [Abstract][Full Text] [Related]
3. Stimulatory effects of low-dose 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor fluvastatin on hepatocyte growth factor-induced angiogenesis: involvement of p38 mitogen-activated protein kinase.
Uruno A; Sugawara A; Kudo M; Satoh F; Saito A; Ito S
Hypertens Res; 2008 Nov; 31(11):2085-96. PubMed ID: 19098381
[TBL] [Abstract][Full Text] [Related]
4. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
Zhang GM; Zhang YM; Fu SB; Liu XH; Fu X; Yu Y; Zhang ZY
Chin Med J (Engl); 2008 Nov; 121(22):2324-30. PubMed ID: 19080341
[TBL] [Abstract][Full Text] [Related]
5. Fluvastatin inhibits regulated secretion of endothelial cell von Willebrand factor in response to diverse secretagogues.
Fish RJ; Yang H; Viglino C; Schorer R; Dunoyer-Geindre S; Kruithof EK
Biochem J; 2007 Aug; 405(3):597-604. PubMed ID: 17472573
[TBL] [Abstract][Full Text] [Related]
6. Fluvastatin synergistically improves the antiproliferative effect of everolimus on rat smooth muscle cells by altering p27Kip1/cyclin E expression.
Ferri N; Granata A; Pirola C; Torti F; Pfister PJ; Dorent R; Corsini A
Mol Pharmacol; 2008 Jul; 74(1):144-53. PubMed ID: 18413661
[TBL] [Abstract][Full Text] [Related]
7. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
8. Hydroxymethyl-glutaryl coenzyme a reductase inhibition limits cytomegalovirus infection in human endothelial cells.
Potena L; Frascaroli G; Grigioni F; Lazzarotto T; Magnani G; Tomasi L; Coccolo F; Gabrielli L; Magelli C; Landini MP; Branzi A
Circulation; 2004 Feb; 109(4):532-6. PubMed ID: 14744969
[TBL] [Abstract][Full Text] [Related]
9. Class-specific pro-apoptotic effect of statins on human vascular endothelial cells.
Mück AO; Seeger H; Wallwiener D
Z Kardiol; 2004 May; 93(5):398-402. PubMed ID: 15160275
[TBL] [Abstract][Full Text] [Related]
10. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
11. HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1.
Morikawa-Futamatsu K; Adachi S; Maejima Y; Tamamori-Adachi M; Suzuki J; Kitajima S; Ito H; Isobe M
Life Sci; 2006 Aug; 79(14):1380-90. PubMed ID: 16712874
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic naked DNA vaccination with the human vascular endothelial growth factor induces an anti-tumor response in C57Bl/6 mice.
Bequet-Romero M; Ayala M; Acevedo BE; Rodríguez EG; Ocejo OL; Torrens I; Gavilondo JV
Angiogenesis; 2007; 10(1):23-34. PubMed ID: 17273909
[TBL] [Abstract][Full Text] [Related]
13. Retinoic acid inhibits angiogenesis and tumor growth of thyroid cancer cells.
Hoffmann S; Rockenstein A; Ramaswamy A; Celik I; Wunderlich A; Lingelbach S; Hofbauer LC; Zielke A
Mol Cell Endocrinol; 2007 Jan; 264(1-2):74-81. PubMed ID: 17101211
[TBL] [Abstract][Full Text] [Related]
14. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
Engel D; Nudelman A; Tarasenko N; Levovich I; Makarovsky I; Sochotnikov S; Tarasenko I; Rephaeli A
J Med Chem; 2008 Jan; 51(2):314-23. PubMed ID: 18163551
[TBL] [Abstract][Full Text] [Related]
15. Effect of HMGCoA reductase inhibitors on cytochrome P450 expression in endothelial cell line.
Bertrand-Thiebault C; Masson C; Siest G; Batt AM; Visvikis-Siest S
J Cardiovasc Pharmacol; 2007 May; 49(5):306-15. PubMed ID: 17513950
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of transendothelial migration and invasion of human breast cancer cells by preventing geranylgeranylation of Rho.
Kusama T; Mukai M; Tatsuta M; Nakamura H; Inoue M
Int J Oncol; 2006 Jul; 29(1):217-23. PubMed ID: 16773203
[TBL] [Abstract][Full Text] [Related]
17. Mutation of human plasminogen kringle 1-5 enhances anti-angiogenic action via increased interaction with integrin alpha(v)beta(3).
Chang PC; Chang YJ; Wu HL; Chang CW; Lin CI; Wang WC; Shi GY
Thromb Haemost; 2008 Apr; 99(4):729-38. PubMed ID: 18392331
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion.
Turner NA; Midgley L; O'Regan DJ; Porter KE
J Cardiovasc Pharmacol; 2007 Oct; 50(4):458-61. PubMed ID: 18049315
[TBL] [Abstract][Full Text] [Related]
19. Fluvastatin prevents oxidized low-density lipoprotein-induced injury of renal tubular epithelial cells by inhibiting the phosphatidylinositol 3-kinase/Akt-signaling pathway.
Chu G; Jia R; Yang D
J Nephrol; 2006; 19(3):286-95. PubMed ID: 16874687
[TBL] [Abstract][Full Text] [Related]
20. Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells.
Taylor-Harding B; Orsulic S; Karlan BY; Li AJ
Gynecol Oncol; 2010 Dec; 119(3):549-56. PubMed ID: 20837358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]